OSE Immunotherapeutics (EPA: OSE) revenue
OSE Immunotherapeutics reported revenue of €2.6m for fiscal 2025; in fiscal 2023 it was €2.2m. Since fiscal 2020 its revenue has fallen by 74.9%, an average decline of 24.2% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | €2.6m | — | −€37.5m | −1,431.3% |
| 2023 | €2.2m | — | −€23.0m | −1,032.2% |
| 2021 | €26.3m | +152.2% | −€16.6m | −63.2% |
| 2020 | €10.4m | — | −€19.0m | −182.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the revenue of OSE Immunotherapeutics
- How much revenue did OSE Immunotherapeutics make in fiscal 2025?
- OSE Immunotherapeutics reported revenue of €2.6m for fiscal 2025, compared with €2.2m in fiscal 2023.
- How much has the revenue of OSE Immunotherapeutics fallen?
- Between fiscal 2020 and fiscal 2025 it went from €10.4m to €2.6m: 74.9% less, an average decline of 24.2% a year.
- What was the best year for revenue at OSE Immunotherapeutics?
- Of its last 4 fiscal years, fiscal 2021, with €26.3m.
- Where do the figures for OSE Immunotherapeutics come from?
- From the report OSE Immunotherapeutics files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report OSE Immunotherapeutics files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2021. More on OSE Immunotherapeutics: the OSE Immunotherapeutics page · annual accounts · net income.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.